SCHEMBL14724028

SCHEMBL14724028

O=C(CCCc1ccc([N+](=O)[O-])cc1)OCI

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
KMT2A Q03164 2/20 0.53
TSHR P16473 1/20 0.51
ALDH1A1 P00352 5/20 0.51
TDP1 Q9NUW8 1/20 0.49
EPHX1 P07099 1/20 0.46
KCNJ1 P48048 2/20 0.46
RAB9A P51151 1/20 0.45
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KCNH2 Q12809 3/20 0.44
BCL9 O00512 1/20 0.43
CTNNB1 P35222 1/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188600 0.87 MAPT (0.55) MAPTKMT2ATSHRALDH1A1TDP1
SCHEMBL5024676 0.87 MAPT (0.52) MAPTKMT2ATSHRALDH1A1TDP1
SCHEMBL9503602 0.86 MAPT (0.56) MAPTKMT2ATSHRALDH1A1TDP1
Hydrochloric Acid SCHEMBL6988461 0.85 MAPT (0.54) MAPTKMT2ATSHRALDH1A1TDP1
SCHEMBL15154022 0.83 MAPT (0.54) MAPTKMT2ATSHRALDH1A1TDP1
SCHEMBL14075558 0.83 MAPT (0.54) MAPTKMT2ATSHRALDH1A1TDP1
SCHEMBL1350599 0.83 MAPT (0.55) MAPTKMT2ATSHRALDH1A1TDP1
SCHEMBL5708169 0.83 MAPT (0.49) MAPTKMT2ATSHRALDH1A1TDP1
SCHEMBL27869674 0.82 ALDH1A1 (0.56) MAPTKMT2ATSHRALDH1A1TDP1
SCHEMBL5708161 0.82 ALDH1A1 (0.67) MAPTKMT2AALDH1A1KCNJ1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383817-B2 S-(+)-2 beta -hydroxymethyl-3 alpha -[bis(4-fluorophenyl)methoxy]tropane; treating mental disorders; reducing food intake; detecting the binding of the compound to the central nervous system tissue to monitor Parkinson's THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2013-02-26 US disclosed